BOOK
Modern Management of High Grade Glioma, Part II, An Issue of Neurosurgery Clinics - E-Book
(2012)
Additional Information
Book Details
Abstract
Standard therapy for high grade glioma is a topic that is evolving, timely, and relevant. Guest Editors Isaac Yang, MD and Seunggu Han, MD have assembled a group of experts on management of high grade glioma. Some of the articles in this issue include: Use of language mapping to aid resection of eloquent gliomas; Clinical trials with immunotherapy; Clinical trials for small molecule inhibitors; Nanotechnology potential applications for GBM therapy; High Grade Gliomas in children; Modern Advances in Brain Tumor Treatments; Molecular pathways of Avastin interactions for the treatment of glioblastoma; and Quality of Life and Outcomes in Glioblastoma management.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Neurosurgery Clinics of North America: Modern Management of High Grade Glioma, Part II | i | ||
| Copyright Page | ii | ||
| Table of Contents | vii | ||
| Contributors | iii | ||
| NEUROSURGERY CLINICS OF NORTH AMERICA | xi | ||
| Preface: Modern Management of High Grade Glioma, Part II | xiii | ||
| Chapter 1. Immunotherapy for Glioma: Promises and Challenges | 357 | ||
| INTRODUCTION | 357 | ||
| TUMOR-ASSOCIATED IMMUNOSUPPRESSION | 358 | ||
| IMMUNOTHERAPY | 359 | ||
| MULTIMODALITY IMMUNOTHERAPY | 362 | ||
| SUMMARY | 363 | ||
| REFERENCES | 363 | ||
| Chapter 2. Glioblastoma Multiforme Treatment with Clinical Trials for Surgical Resection (Aminolevulinic Acid) | 371 | ||
| EARLY WORK | 372 | ||
| THE GERMAN MULTI-INSTITUTIONAL TRIAL | 372 | ||
| DARTMOUTH STUDIES | 374 | ||
| PROPOSED RTOG TRIAL | 376 | ||
| SUMMARY | 376 | ||
| REFERENCES | 376 | ||
| Chapter 3. Potential Role for STAT3 Inhibitors in Glioblastoma | 379 | ||
| INTRODUCTION | 379 | ||
| STAT3 SIGNALING PATHWAY | 380 | ||
| ROLE OF STAT3 IN ONCOGENESIS | 380 | ||
| APPROACHES TO STAT3 INHIBITION | 383 | ||
| SUMMARY | 384 | ||
| REFERENCES | 384 | ||
| Chapter 4. CD133 as a Marker for Regulation and Potential for Targeted Therapies in Glioblastoma Multiforme | 391 | ||
| INTRODUCTION | 391 | ||
| DISCOVERY OF CD133 | 392 | ||
| CD133 AS A STEM CELL MARKER | 392 | ||
| CD133¯ CELLS IN GLIOMAS | 394 | ||
| LINKING CD133¯ AND CD133D+ SUBPOPULATIONS | 395 | ||
| CONTRIBUTION TO ANGIOGENESIS | 398 | ||
| THERAPEUTIC POTENTIAL | 400 | ||
| ACKNOWLEDGMENTS | 401 | ||
| REFERENCES | 401 | ||
| Chapter 5. Clinical Trials of Small Molecule Inhibitors in High-Grade Glioma | 407 | ||
| CHEMOTHERAPY: OPPORTUNITIES FOR OPTIMIZATION IN HIGH-GRADE GLIOMA | 407 | ||
| WHAT IS AN SMI? | 408 | ||
| EPIDERMAL-DERIVED GROWTH FACTOR RECEPTOR | 408 | ||
| PLATELET-DERIVED GROWTH FACTOR RECEPTOR | 409 | ||
| VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR | 410 | ||
| INHIBITION OF INTRACELLULAR SIGNALING CASCADES | 410 | ||
| RAS/RAF | 410 | ||
| PI3K | 411 | ||
| β-PROTEIN KINASE C | 411 | ||
| OTHER AGENTS | 411 | ||
| FUTURE DIRECTIONS | 412 | ||
| REFERENCES | 413 | ||
| Chapter 6. Molecular Characteristics and Pathways of Avastin for the Treatment of Glioblastoma Multiforme | 417 | ||
| INTRODUCTION | 417 | ||
| MOLECULAR MECHANISM OF BEVACIZUMAB | 418 | ||
| VEGF AND BEVACIZUMAB | 420 | ||
| THE EFFECT OF BEVACIZUMAB ON OTHER TREATMENTS | 421 | ||
| SUMMARY | 424 | ||
| REFERENCES | 424 | ||
| Chapter 7. Potential Usefulness of Radiosensitizers in Glioblastoma | 429 | ||
| INTRODUCTION | 429 | ||
| RADIOSENSITIZATION: A CONCEPTUAL BASIS | 430 | ||
| INHIBITION OF DNA REPLICATION | 431 | ||
| MICROTUBULE STABILIZERS/DESTABILIZERS | 433 | ||
| AUGMENTATION OF REDOX STRESS | 433 | ||
| INHIBITION OF ANGIOGENESIS | 434 | ||
| SIGNAL PATHWAY INHIBITION | 435 | ||
| FUTURE DIRECTIONS | 435 | ||
| REFERENCES | 435 | ||
| Chapter 8. Nanotechnology Applications for Glioblastoma | 439 | ||
| INTRODUCTION | 439 | ||
| MAGNETIC NANOPARTICLES | 440 | ||
| NANOPARTICALIZED CHEMOTHERAPEUTIC AGENTS | 442 | ||
| GENE DELIVERY WITH NANOPARTICLES | 442 | ||
| NANOPARTICLES FOR BRACHYTHERAPY | 443 | ||
| GOLD NANOPARTICLE PHOTOTHERAPY | 443 | ||
| MALIGNANT BRAIN TUMOR DELIVERY OF NANOPARTICLES | 443 | ||
| Chapter 9. Endogenous Vaults and Bioengineered Vault Nanoparticles for Treatment of Glioblastomas: Implications for Future Targeted Therapies | 451 | ||
| INTRODUCTION | 452 | ||
| VAULT NANOPARTICLES: AN OVERVIEW | 452 | ||
| MVP: THE MVP SUBUNIT | 453 | ||
| vPARP: THE vPARP SUBUNIT | 453 | ||
| TEP1: THE TEP1 SUBUNIT | 453 | ||
| UNTRANSLATED RNA | 454 | ||
| VAULTS AND THE CNS | 454 | ||
| POTENTIAL USES FOR FUTURE THERAPIES | 454 | ||
| SUMMARY | 455 | ||
| ACKNOWLEDGMENTS | 455 | ||
| REFERENCES | 455 | ||
| Chapter 10. Clinical Trials with Immunotherapy for High-Grade Glioma | 459 | ||
| INTRODUCTION | 459 | ||
| ADOPTIVE IMMUNOTHERAPY | 460 | ||
| ACTIVE IMMUNOTHERAPY | 462 | ||
| IMMUNOMODULATION | 463 | ||
| CHALLENGES | 465 | ||
| SUMMARY | 465 | ||
| REFERENCES | 466 | ||
| Chapter 11. IDH Mutations in Human Glioma | 471 | ||
| INTRODUCTION | 471 | ||
| IDH1: FUNCTION | 471 | ||
| IDH1 MUTATIONS IN HUMAN GLIOMA | 472 | ||
| PUTATIVE ROLE OF IDH1 MUTATIONS IN GLIOMAGENESIS | 473 | ||
| IDH1 MUTATIONS AND OTHER GLIOMA-ASSOCIATED GENETIC CHARACTERISTICS | 474 | ||
| ROLE OF IDH1 MUTATION IN PROGNOSIS AND RESPONSE TO TREATMENT IN HUMAN GLIOMA | 475 | ||
| DETECTION OF IDH1 MUTATIONS | 475 | ||
| IDH MUTATIONS IN OTHER BRAIN TUMORS | 476 | ||
| SUMMARY | 477 | ||
| REFERENCES | 477 | ||
| Chapter 12. Passive Immunotherapeutic Strategies for the Treatment of Malignant Gliomas | 481 | ||
| PASSIVE IMMUNOTHERAPY | 481 | ||
| AIT: LAK CELLS | 482 | ||
| AIT: CTL | 483 | ||
| ANTIBODY-MEDIATED IMMUNOTHERAPY | 486 | ||
| SUMMARY | 490 | ||
| REFERENCES | 490 | ||
| Chapter 13. Use of Language Mapping to Aid in Resection of Gliomas in Eloquent Brain Regions | 497 | ||
| INTRODUCTION | 497 | ||
| RATIONALE FOR EXTENSIVE RESECTION | 498 | ||
| PREOPERATIVE IMAGING FOR LANGUAGE MAPPING | 499 | ||
| INTRAOPERATIVE LANGUAGE TESTING AND ESM | 501 | ||
| POSTOPERATIVE GOALS AND ASSESSMENT | 503 | ||
| SUMMARY | 504 | ||
| REFERENCES | 504 | ||
| Chapter 14. Quality of Life and Outcomes in Glioblastoma Management | 507 | ||
| INTRODUCTION | 507 | ||
| RADIOLOGICAL CONSIDERATIONS ON THE QUALITY OF LIFE AND OUTCOMES IN GBM | 508 | ||
| SURGICAL CONSIDERATIONS ON THE QOL AND OUTCOMES IN GBM | 508 | ||
| RADIOTHERAPY CONSIDERATIONS ON THE QUALITY OF LIFE AND OUTCOMES IN GBM | 509 | ||
| CHEMOTHERAPEUTIC CONSIDERATIONS ON THE QOL AND OUTCOMES IN GBM | 510 | ||
| VALUE OF HOSPICE CARE | 511 | ||
| SUMMARY | 512 | ||
| ACKNOWLEDGMENTS | 512 | ||
| REFERENCES | 512 | ||
| Chapter 15. High-Grade Gliomas in Children | 515 | ||
| INTRODUCTION | 515 | ||
| EPIDEMIOLOGY | 515 | ||
| PATHOLOGY | 516 | ||
| TREATMENT | 518 | ||
| OUTCOME | 520 | ||
| FUTURE DIRECTIONS | 520 | ||
| SUMMARY | 521 | ||
| REFERENCES | 521 | ||
| Index | 525 |